Navigation Links
Small Company Contests Big Pharma’s Patent Challenge

This month, Prollenium Medical Technologies, Inc. filed its answer and counterclaims to a lawsuit by Allergan (C.A. No. 19-126-CFC, filed in the United States District Court for the District of Delaware). Allergan alleges that Prollenium’s hyaluronic acid (HA) dermal filler, Revanesse Versa+, infringes upon several patents it holds, relating to its injectable gel fillers.

The patents in question cover formulations for and methods of manufacturing HA dermal fillers that include lidocaine. Lidocaine is an anesthetic drug that was discovered in 1946 and is widely used for pain treatment in procedures as varied as dental surgery, mole removal, cataract correction, biopsies and nerve blocks. It is included on the World Health Organization’s List of Essential Medicines. For over fifteen years, it’s been used to add comfort to treatments in the medical aesthetic industry.

In its answer and counterclaim, Prollenium Medical Technologies contests the claims and contends that the patents to which they refer – patents on HA compositions cross-linked with butanediol diglycidyl ether (BDDE) and containing lidocaine – are invalid because they claim what was already well known in the art. In its counterclaim Prollenium also alleges that, “Allergan’s patents for cross-linked HA dermal fillers containing Lidocaine, are unenforceable because they are founded on misstatements made to the United States Patent Office, about information that were material to the patentability of the claims.”

“In our opinion, they are using the US patent office as a tool to limit patient and provider choice, and to keep drug costs high. In filing baseless patents, then suing smaller manufacturers to try to enforce them, we believe, they are endeavoring to ensure that they have sole rights to leverage a commonly used, elemental ingredient that eases patient discomfort,” said Khasha Ighanian, President of Prollenium.

“Patents should stimulate innovation and contribute to technological progress. We feel that by patenting the use of a well-understood composition with a common ingredient like lidocaine, they are using the patent system to stifle competition and choice,” said Ario Khoshbin, Prollenium CEO and Founder.

He continued, “We include lidocaine in our product because we believe that patient wellness and comfort can be and should be available to patients and providers as a standard, not a luxury.”

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related medicine technology :

1. Pediatric Surgeon Dr. Philip K. Frykman Receives NIH Grant for Research on HAEC, a Potentially Deadly Complication Threatening Infants and Small Children.
2. CarePlus™ Direct is Here, Ensuring Nurse Call is More Accessible to Managers at Day Surgeries and Small Clinics
3. Nutritional Supplement Company Offers Small & Medium Sized Companies Group Discounts
4. National Award Winning Small Town Company Strikes Gold with Charcoal
5. BCMA Targeted Therapies, 2017-2030: Even Though Big Pharmaceutical Companies Dominate the Current Space, Several Start-Ups/Small Companies Have Emerged - Research and Markets
6. Regen BioPharma, Inc. Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6
7. Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Markets to 2023: Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market - Research and Markets
8. Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Cancer to Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
9. Heptares Therapeutics Enters Agreement With Daiichi Sankyo to Discover and Develop Novel, Small-molecules for the Treatment of Pain
10. Global Non-Small Cell Lung Cancer Partnering 2010 to 2017
11. BeyondSprings Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Post Your Comments:
(Date:6/14/2019)... ... June 14, 2019 , ... Land O' Lakes ... the release of their new website designed to help patients obtain useful information, read ... Land O’ Lakes, Florida Chiropractor, Dr. Michael Craven is committed to helping ...
(Date:6/13/2019)... ... June 13, 2019 , ... Alliance Cost Containment, LLC ... in the healthcare space. The $5.8M in savings is in addition to $17.6M saved ... $23.4M. , With an acquisition in Q4 2019, the client increased their Fortune 500 ...
(Date:6/13/2019)... ... June 13, 2019 , ... Homecare Homebase ... the new Smart Scheduling product, part of the HCHB Intelligence Suite, at the ... uses complex algorithms to create highly efficient routing, mapping and scheduling for home ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... Clinical Ink , a global ... announce that Jonathan Andrus , chief business officer at Clinical Ink, has been ... Center for Health Policy on July 1, 2019, in Washington, D.C. The workshop, ...
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School ... Science in Health Informatics (MSHI ) degree program to address the growing need for ... program is part of a larger effort for SHRS to bring more graduate degrees ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving ... being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose ...
(Date:6/12/2019)... ... June 12, 2019 , ... NDA Partners Chairman ... more than 25 years of experience in quality systems development, quality systems management, ... devices, has joined NDA Partners as an Expert Consultant. Her experience includes quality ...
(Date:6/12/2019)... ... 2019 , ... Ovation Travel Group, one of the largest ... Chairman and CEO Paul Metselaar has received the Children’s Health Fund’s Founder’s Award, ... New York City’s Capitale as part of the Children’s Health Fund’s 2019 Annual ...
Breaking Medicine News(10 mins):